Vamifeport reduced systemic and vascular inflammation, and oxidative stress, in HbSS mice. Vamifeport significantly reduced inflammatory markers in HbSS mice: total leukocyte, neutrophil, and lymphocyte counts (A); plasma levels of the chemokine RANTES (B); expression of the neutrophil chemoattractant Cxcl1, as determined by quantitative polymerase chain reaction in liver (C); sVCAM-1 (D); soluble P-selectin (E); and plasma XO activity (F). Results are presented as individual values with mean ± standard deviation (n = 6-8 mice per group). Analysis was performed by using one-way analysis of variance with Dunnett’s multiple comparison of all groups vs the HbSS vehicle group: *P < .05, **P < .01, ***P < .001. BID, twice daily.